Tirzepatide mechanism research in Canada investigates how this dual GIP and GLP-1 receptor agonist produces superior weight loss and glycaemic control compared to single GLP-1 agonists. Tirzepatide (LY3298176) is a 39-amino acid synthetic peptide with C18 fatty diacid conjugation that activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor (GLP-1R). Canadian metabolic disease researchers study the pharmacological synergy between GIP and GLP-1 receptor co-activation and how their combined signalling produces incremental metabolic benefits over GLP-1R agonism alone.
GIP Receptor Pharmacology Research
GIP (glucose-dependent insulinotropic polypeptide) is produced by K-cells in the duodenum and jejunum. GIPR is expressed on pancreatic beta cells, adipose tissue, bone, and the CNS. GIPR activation in beta cells potentiates glucose-stimulated insulin secretion through cAMP/PKA and EPAC pathways. In adipose tissue, GIPR may promote lipid uptake and reduce lipotoxicity. Canadian researchers study how tirzepatide’s GIPR activity complements GLP-1R signalling in beta cells and adipose tissue.
Additive Weight Loss Research
Clinical research shows tirzepatide produces greater weight loss than semaglutide. Canadian obesity researchers study whether GIPR agonism adds central appetite-suppressive effects through hypothalamic GIPR, reduces lipid accumulation in adipocytes, or synergizes with GLP-1R CNS signalling to produce stronger satiety signals. GIPR in the VTA and hypothalamus is a focus of Canadian neuroendocrine research.
Sourcing Tirzepatide in Canada
Research-grade tirzepatide is available from EhBuddy Peptides in Canada. Lab-tested for purity. For laboratory research use only.
Tirzepatide represents the most studied dual incretin agonist in Canadian metabolic disease research, making it central to understanding GIP/GLP-1 receptor co-activation biology.
